Recent studies have raised concern that macrolide antibiotics may be associated with an increased long-term risk of cardiovascular death. We examined the 1-year risk associated with treatment with clarithromycin (n = 187,887) or roxithromycin (n = 698,899) compared with penicillin V (n = 3,473,081), matched 1:4 on propensity score, in a nationwide, registry-based cohort study in Danish outpatients, 1997-2011. Among clarithromycin courses, the rate ratio for cardiovascular death was 1.24 (95% confidence interval (CI): 0.96, 1.59). Among roxithromycin courses, the rate ratio was 0.99 (95% CI: 0.86, 1.16). In analyses by time after treatment start, the rate ratio associated with clarithromycin was 1.66 (95% CI: 0.98, 2.79) during days 0-7. This was attenuated in later time periods (days 8-89, rate ratio = 1.30, 95% CI: 0.88, 1.94; and days 90-364, rate ratio = 0.96, 95% CI: 0.63, 1.47). For roxithromycin, the rate ratios were 0.88 (95% CI: 0.59, 1.32) during days 0-7, 1.17 (95% CI: 0.92, 1.48) during days 8-89, and 0.88 (95% CI: 0.70, 1.10) during days 90-364. We found no increased risk of cardiovascular death in a general outpatient population. With clarithromycin, we observed a transient increased risk during days 0-7 after treatment start, which corresponds to the period of active treatment. This association was absent in later time periods, which is consistent with no long-term toxicity resulting in cardiovascular death. cardiovascular death; clarithromycin; epidemiology; macrolides; roxithromycin Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; RR, rate ratio.
The widely used macrolide antibiotics have increasingly been associated with an unfavorable cardiac safety profile (1, 2) . Macrolides are partial blockers of the cardiac potassium channel, and several agents in this drug class have been associated with prolongation of the QT interval, which could potentially increase the risk of torsade de pointes, a life-threatening cardiac arrhythmia (3) . Several case reports support this association, but data from clinical trials are limited due to the rare outcome of the event. While some observational studies report an increased risk of cardiac death or arrhythmia associated with the use of azithromycin (4) (5) (6) and erythromycin (7) , results from an observational cohort study conducted in a low-risk population did not support an increased risk with azithromycin use (8) . The cardiac safety of clarithromycin and roxithromycin is less explored. A recent populationbased cohort study from our group found an increased shortterm risk of cardiac death associated with current use of (active treatment with) clarithromycin but not with roxithromycin (9) .
Whereas interference with the cardiac potassium channel and associated arrhythmia represent a transient toxic effect, concerns have also been raised regarding the long-term cardiac safety of clarithromycin. In a randomized, placebo-controlled trial in patients with stable coronary heart disease, a 2-week clarithromycin course was associated with sustained increased cardiovascular mortality during 3 years of follow-up, implying a delayed toxic mechanism (10) . These findings were unexpected and were not reproduced in meta-analyses of macrolides in ischemic heart disease (11, 12) or reported from clinical trials of long-term macrolide treatment in chronic obstructive pulmonary disease (COPD) (13, 14) . The use of clarithromycin was not associated with long-term increased risk of death when prescribed for Helicobacter pylori eradication (15, 16) or in a recent observational cohort study (17) . However, a study in cohorts of patients with community-acquired pneumonia and acute exacerbation of COPD reported an increased 1-year risk of cardiovascular events after a short-course treatment with clarithromycin (18) .
Given these discrepant reports, we conducted a registrybased cohort study in an unselected general population, to assess whether short-term use of clarithromycin or roxithromycin was associated with an increased long-term risk of cardiovascular death compared with penicillin V, an antibiotic without known cardiovascular side effects.
METHODS
We conducted a study in a historical cohort of Danish adults, 1997-2011, by linking individual information retrieved from national health registers. We estimated the risk of cardiovascular death associated with the use of clarithromycin or roxithromycin in time periods up to 1 year after start of treatment. To reduce the potential for confounding by indication, we compared courses with clarithromycin and courses with roxithromycin with courses of penicillin V, a comparator antibiotic without known or suspected cardiac side effects. Penicillin V is the most commonly used antibiotic in Denmark. Indications overlap for treatment of respiratory infections. Additionally, the macrolides are used for treatment of atypical pneumonia agents, such as Legionella and Mycoplasma, and clarithromycin is included in the treatment regimen for H. pylori eradication.
To reduce the potential for confounding from baseline characteristics at the start of treatment, courses of clarithromycin and penicillin V and, separately, roxithromycin and penicillin V were matched 1:4 on the propensity score, yielding 2 separate, matched study cohorts, one for each macrolide. The risk associated with the study macrolide was also assessed according to time after treatment start and according to subgroups of age, sex, and underlying cardiac disease as estimated by a cardiovascular risk score. Furthermore, we analyzed the outcome of other noncardiovascular death. An increased risk of death due to other causes for any of the other study drugs could indicate differential health status at baseline or differential severity of the infections for which the study antibiotics were prescribed.
The study was based on a source population of all individuals aged 40-74 years, living in Denmark during the study period, identified through the Danish Civil Registration System (19) . Data on filled prescriptions for clarithromycin (Anatomical Therapeutic Chemical (ATC) code J01FA09), roxithromycin (code J01FA06), and penicillin V (code J01CE02) were obtained from the Danish National Prescription Registry (20) . Individual-level information on outcomes and potential confounders at the start of treatment-such as comorbidity, prior health-care utilization, medications, and demographic characteristics-was obtained from the Danish National Patient Registry (21), the Danish Register of Causes of Death (22) , the Danish National Prescription Registry, and the Danish Civil Registration System. There were no missing data. Crossreferencing of databases was possible using the unique civil registration identification number that is assigned to all people living in Denmark. To ensure adequate capture of information in the national databases, participants were required to have been registered in Denmark for a minimum of 2 years before the prescription date (index date). Each prescription was considered separately, and each individual could contribute more than 1 treatment course. Treatment courses were not allowed to overlap. We excluded courses from individuals who had filled any antibiotic prescription or who had been admitted to hospital within 30 days before or on the index date. To reduce the potential for confounding and to increase the ability to isolate an effect attributed to the study drugs, we excluded individuals with a history of substance misuse or serious noncardiovascular disease, who might be at relatively higher risk of death from other causes at start of follow-up. A complete list of exclusion criteria is given in Web Table 1 (available at https://academic.oup.com/aje). The study was approved by the Danish Data Protection Agency; ethics approval is not required for register-based research in Denmark.
The main outcome, cardiovascular death, was defined by one of the following codes from the International Classification of Diseases, Tenth Revision (ICD-10), recorded in the Causes of Death registry: ischemic heart disease (codes I20-I25); arrhythmic disorders, cardiac arrest, or heart failure (codes I44-I50); cerebral infarction (code I63); or atherosclerosis (code I70). We also analyzed death from any other cardiovascular cause (codes I10-I99, except those included in the main outcome) and noncardiovascular cause of death (all codes except I10-I99). Follow-up started on the date the prescription was filled and ended on the date of death, participant reaching 75 years of age, loss to follow-up (emigration, disappearance), hospitalization, filling a prescription for any antibiotic, end of study (December 31, 2011), or 365 days after the prescription date, whichever came first. In the analyses of death due to other causes, hospital admission was not used as censoring criterion.
We used propensity scores to control for confounding (23) . The individual propensities for clarithromycin or roxithromycin treatment, versus penicillin V, were estimated in 2 separate logistic regression models, including all covariates listed in Web Table 2 as predictors. Courses of clarithromycin and roxithromycin were then matched to courses of penicillin V on a ratio of 1:4 on the propensity score, using the greedy 5-to-1 digit matching algorithm (24, 25) . Balance between groups was assessed by estimating the standardized differences and was considered well-balanced if below 10%.
A risk score for cardiovascular death to be used in subgroup analyses was empirically derived, using a logistic regression model, including all predictors listed in Table 1 and an indicator variable for the antibiotic received. The individual risk score was calculated by multiplying the regression coefficients by the covariate values for all predictors but the treatment variables, which were set to 0 and categorized into 3 groups according to the score's distribution: low (deciles 1-5), moderate (deciles 6-8), and high (deciles 9-10) (26).
We estimated rate ratios for cardiovascular death with the use of clarithromycin or roxithromycin, compared with the use of penicillin V, using Poisson regression. In secondary analyses we subdivided time of follow-up into 0-7 days (representing active treatment or "current use"), 8-89 days, or 90-364 days from start of treatment. Rate ratios for cardiovascular death were also estimated in subgroups of participants, categorized according to age, sex, and cardiovascular risk score. Homogeneity of treatment effect estimates across subgroups was assessed using likelihood ratio tests. All statistical tests were 2-sided; 95% confidence intervals that did not overlap 1.0 and P values less than 0.05 were considered statistically significant. Analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
From a source population of 3,380,262 Danish adults, we identified 415,297 courses of clarithromycin, 1,150,387 courses of roxithromycin, and 7,345,765 courses of penicillin V. The inclusion criteria were met for 187,887 courses of clarithromycin, 698,899 courses of roxithromycin, and 5,395,462 courses of penicillin V. After propensity score estimation and matching, the cohort used for the analyses of clarithromycin versus penicillin V consisted of 187,887 courses of clarithromycin and 751,543 courses of penicillin V. The cohort used for the analyses of roxithromycin versus penicillin V included 698,899 courses of roxithromycin and 2,721,538 courses of penicillin V. For clarithromycin use, 29,310 individuals contributed more than 1 antibiotic course, and for roxithromycin use, 129,976 contributed more than 1 course. A flowchart of the cohort selection is shown in Figure 1 .
Baseline characteristics for the unmatched cohorts are shown in Web Table 3 . Before matching, individuals in the groups treated with clarithromycin or roxithromycin were more likely to be of female sex and have an underlying respiratory disease. The odds ratios for the propensities for clarithromycin and roxithromycin for all variables are provided in Web Table 4 . After propensity score matching, the treatment groups in both cohorts were well-balanced on all baseline characteristics (Table 1 and  Web Table 5 ); although a history of respiratory disease and use of inhalants for obstructive lung disease was slightly more common among roxithromycin users, the standardized differences were within acceptable limits for good balance. For clarithromycin, 55% of courses were censored due to a new prescription of antibiotics and 9% due to hospitalization, as compared with 54% and 8%, respectively, for the matched penicillin courses. For roxithromycin, 52% courses were censored due to a new prescription of antibiotics and 8% due to hospitalization, as compared with 51% and 8%, respectively, for the matched penicillin courses. Table 2 shows the risk of cardiovascular death associated with clarithromycin or roxithromycin exposure. Among courses of clarithromycin, a total of 78 cardiovascular deaths occurred during follow-up (overall incidence rate = 0.8 per 1,000 personyears); 259 deaths occurred among the corresponding control courses with penicillin V (0.6 per 1,000 person-years), yielding a rate ratio of 1.24 (95% confidence interval (CI): 0.96, 1.59). There was a tendency toward an increased risk of cardiovascular death during days 0-7 after start of treatment of clarithromycin compared with penicillin V; the rate ratio was 1.66 (95% CI: 0.98, 2.79), which was attenuated in later periods of follow-up. The rate ratio for days 8-89 was 1.30 (95% CI: 0.88, 1.94) and for days 90-364 was 0.96 (95% CI: 0.63, 1.47).
For courses of roxithromycin, 211 cardiovascular deaths occurred during 1 year of follow-up (incidence rate = 0.6 per 1,000 person-years), and 858 deaths occurred among the control courses with penicillin V (0.6 per 1,000 person-years), for a rate ratio of 0.99 (95% CI: 0.86, 1.16). The rate ratio for days 0-7 after start of treatment was 0.88 (95% CI: 0.59, 1.32); during days 8-89, the rate ratio was 1.17 (95% CI: 0.92, 1.48), and it was 0.88 (95% CI: 0.70, 1.10) during days 90-364.
For clarithromycin, the 1-year risk of cardiovascular death was more pronounced in women, (rate ratio (RR) = 1.69, 95% CI: 1.14, 2.48) than in men (RR = 1.00, 95% CI: 0.71, 1.40) (P for homogeneity P = 0.05). For women, the rate ratio for cardiovascular death associated with clarithromycin was 2.82 (95% CI: 1.35, 5.90) for days 0-7 after start of treatment; for days 8-89 the rate ratio was 1.60 (95% CI: 0.86, 2.98), and for days 90-364 the rate ratio was 1.16 (0.58, 2.34). For men, the rate ratio for cardiovascular death associated with clarithromycin was 1.02 (95% CI: 0.47, 2.22) for days 0-7 after start of treatment; for days 8-89, the rate ratio was 1.14 (95% CI: 0.67, 1.92), and for days 90-364 the rate ratio was 0.86 (95% CI: 0.50, 1.47). Values for the exclusion criteria do not sum to the totals shown, because some records were excluded for multiple reasons. Individuals with serious substance-misuse or noncardiovascular disease, who might be at relatively higher risk of death from other causes at start of follow-up were excluded (cancer (n = 574,839), serious neurologic disease (n = 71,493), congenital anomalies/childhood conditions (54,421), liver disease (n = 95,071), end-stage renal disease (n = 15,116), serious respiratory disease (n = 130,618), human immunodeficiency virus/acquired immune deficiency syndrome (n = 10,555), other end-stage illness (n = 28,446), dementia (n = 73,741), drug abuse (n = 95,538), alcohol abuse (n = 369,248), psychosis (n = 30,792), and organ transplant (n = 7,379)).
We observed no differences across subgroups of age (P = 0.82) or across levels of cardiac risk score (P = 0.52). For roxithromycin compared with penicillin V, no statistically significant differences were observed in the subgroups according to age (P = 0.11), sex (P = 0.84), underlying cardiac disease (P = 0.84), or levels of cardiac risk score (P = 0.90). Table 3 shows 1-year risk of other cardiovascular death and noncardiovascular death associated with use of clarithromycin or roxithromycin compared with penicillin V. The risk of other cardiovascular death was not increased for courses of clarithromycin compared with courses of penicillin V (RR = 0.86, 95% CI: 0.57, 1.29) or in courses of roxithromycin compared with penicillin V (RR = 0.97, 95% CI: 0.79, 1.21). The risk of noncardiovascular mortality was slightly increased for courses of clarithromycin compared with courses of penicillin V (RR = 1.10, 95% CI: 1.00, 1.22) as well as in courses of roxithromycin compared with penicillin V (RR = 1.20, 95% CI: 1.14, 1.27).
In a sensitivity analysis using only the first antibiotic course, the rate ratio was 1.16 (95% CI: 0.75, 1.79) for courses of clarithromycin compared with penicillin V, with a rate ratio of 0.93 (95% CI: 0.70, 1.23) for courses of roxithromycin compared with penicillin V. In a post-hoc sensitivity analysis, not censoring on hospitalization, the rate ratio was 1.04 (95% CI: 0.87, 1.26) for clarithromycin and 1.00 (95% CI: 0.90, 1.11) for roxithromycin. To address potential misclassification of causes of death, we performed a sensitivity analysis of all-cause mortality, which yielded a rate ratio of 1.06 (95% CI: 0.98, 1.16) for clarithromycin and 1.12 (95% CI: 1.07, 1.18) for roxithromycin.
DISCUSSION
The results of this large population-based cohort study do not support the presence of a long-term risk of cardiovascular death associated with administration of clarithromycin or roxithromycin as compared with penicillin V. Consistent with previous work, a tendency toward increased risk of cardiovascular death associated with clarithromycin in the 0-7 days after treatment start, the time period mirroring current use, was observed (9, 17) . However, this association was attenuated beyond these first days and was completely absent in the period of 90-364 days after treatment start, which is consistent with no delayed toxicity resulting in cardiovascular death. Although long-term side effects of macrolides have been assessed in studies of patients with ischemic heart disease and COPD, only a few studies have examined clarithromycin and roxithromycin specifically (11) (12) (13) (14) . In line with our findings, none of the 4 randomized trials using roxithromycin as an active agent in trials of ischemic heart disease found any significant increased risk of cardiovascular events (27) (28) (29) (30) , nor did 2 of the clinical trials assessing clarithromycin treatment (31) . In the third study (CLARICOR), a 2-week clarithromycin course was unexpectedly associated with 20% increased risk of cardiovascular mortality during 3 years of follow-up (10) . The validity of this result has, however, been questioned because only 32% of potentially eligible patients were randomized, and there was an imbalance in smoking status at baseline despite randomization, implying that associated important differences in health status, most notably the extent of preexisting cardiac disease, could have confounded the results (32) . Moreover, an observational study from the United Kingdom raised concern by reporting an increased 1-year risk of cardiovascular events associated with clarithromycin compared with other antibiotics, in 2 cohorts of patients hospitalized for acute exacerbations of COPD or community-acquired pneumonia during 1 year of follow-up (18) . However, this study analyzed a population with a presumed high baseline risk of cardiovascular morbidity, and so results may not be generalizable to a general outpatient population.
Contrary to this, in a Danish study, clarithromycin prescribed for eradication of H. pylori was not associated with an increased risk of cardiovascular mortality or myocardial infarction during 5 years of follow-up, but this cohort was limited to patients with ischemic heart disease (15) . Similar findings were reported in a recent British observational study in a cohort of outpatients receiving a H. pylori eradication treatment course containing clarithromycin compared with H. pylori eradication without clarithromycin. In this study, authors found a transient increased risk associated with current use (active treatment), but no evidence for a delayed increased risk of myocardial infarction or cardiovascular death (16) . In a cohort study from Hong Kong, current use of clarithromycin was associated with an increased risk of cardiac death, and results were confirmed in a secondary, self-controlled case-series analysis of clarithromycin as part of triple therapy for H. pylori eradication within the same database (17) . In line with our findings, no increased risk was observed in the follow-up periods when treatment had ended. However, H. pylori infection is associated with gastrointestinal bleeding and can thereby indirectly affect the risk of myocardial infarction, which may have influenced estimates. For the present study, we excluded participants with concurrent prescriptions for multiple antibiotics, which should have removed courses of clarithromycin that were part of triple therapy for H. pylori eradication, thereby minimizing the impact of this potential source of bias.
It is known that female sex is a risk factor for drug-induced cardiac arrhythmia (3) . Consistent with this, we observed a higher relative risk for clarithromycin in women than in men, which was restricted to the first days after start of treatment, corresponding to current use. In all of the other subgroups of participants, the results were homogeneous, and we did not observe any increased long-term risk.
Our study has a number of strengths. First, it is, to our knowledge, the largest known study of this association, and it has nationwide coverage, which makes results generalizable to a general, adult outpatient population. Second, we used a comparative design to minimize confounding by indication, comparing 2 different macrolides with penicillin V, an antibiotic without known cardiovascular side effects, and we used we used propensity score matching to control for confounding and balance the treatment arms on a large range of baseline health factors. Finally, we excluded individuals with serious, end-stage diseases, in order to be able to isolate an effect attributable to the study drugs, and we censored individuals with subsequent antibiotic prescription or hospitalization. A limitation of the study is that information on important risk factors for cardiovascular death, such as smoking or body mass index, is not available in national health registers and thus residual confounding cannot be ruled out. However, our results were homogeneous across subgroups of cardiovascular risk, suggesting that the results hold true despite potentially differential distribution of risk factors for cardiovascular disease. Another limitation is the lack of information about the indication for treatment. Despite overlapping indications for respiratory infections, the distributions of specific infections may differ between the study antibiotics. However, the main underlying reason for confounding by indication would be differences in the severity of infections, translated into increased risk of noncardiovascular death. Given the hypothesis of increased risk associated with clarithromycin and roxithromycin and given the null finding, the major concern would be more severe infection in the penicillin V comparator group that biased results towards the null. Reassuringly, the mortality due to noncardiovascular causes was not higher in the penicillin group, which limits the potential for confounding by indication.
In the main analyses, courses were censored on hospitalization in order to be able to separate the effect of the study drugs. The sensitivity analyses, not censoring on hospitalization, yielded very similar results to the main analyses.
The outcome has not been formally validated. However, the validity of the Danish Patient and Causes of Death registries is generally high (22) . In previous studies of myocardial infarction and cardiac death, the predictive value has been estimated to be around 95% for myocardial infarction as underlying cause of death (22, 33) . The sensitivity analyses of all-cause mortality showed very similar results to the main analyses, which limits concerns over misclassification of the causes of death.
We observed a small increased risk of noncardiovascular death among clarithromycin and roxithromycin users compared with penicillin V users, which may reflect that the different treatment groups were imbalanced to a slight extent regarding underlying respiratory diseases and appurtenant medication despite propensity score matching.
In conclusion, we could not find support for a delayed increased risk of cardiovascular mortality associated with clarithromycin or roxithromycin compared with penicillin V in a general outpatient population. Further research is needed, including among individuals with severe infections requiring hospitalizations, especially in populations with a high baseline risk of cardiovascular disease.
